Novartis
NEWS
It was another busy week for clinical trial news. Here’s a look.
Shares of Xencor, Inc. are down nearly 6% after the company announced Novartis terminated its rights to develop vibecotamab, a CD123 x CD3 blood cancer bispecific.
The study was momentous in that it was the first head-to-head comparison of two modalities. The Aimovig showed significantly good results and aced primary endpoints.
Vaccinations will be required by January 4 under the new White House plan.
For the past 20 years, Novartis has held a 33% stake in Roche, its Basel, Switzerland neighbor. Now, Novartis has divested its one-third stake to Roche for a whopping $20.7 billion.
Novartis has forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.
Scemblix is the first-in-class FDA-approved treatment for adult patients diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia.
Yet another busy week for clinical trial news. Here’s a look.
Novartis is the subject of a DOJ inquiry over the company’s marketing and pricing of Entresto over the past five years, receiving a Civil Investigative Demand from the government.
JOBS
IN THE PRESS